BTLA在肿瘤免疫中的作用及其临床意义

The biological function and clinical significance of BTLA in tumor immunity

继程序死亡分子(PD-1)与细胞毒性T细胞相关抗原-4(CTLA-4)之后,CD28家族的新成员B、T淋巴细胞弱化因子(BTLA)已成为新的研究热点。BTLA表达谱介于PD-1和CTLA-4之间,它不仅表达于T细胞,在B细胞、NK细胞、巨噬细胞和树突状细胞中也有表达。BTLA与其配体结合传递共抑制信号,在机体抗肿瘤免疫应答中发挥负性调节作用,并与肿瘤的免疫逃逸机制相关,可能成为肿瘤生物治疗潜在的靶点。

B and T lymphocyte attenuator（ BTLA）, a new inhibitory receptor of the CD28 family, attracts more and more atten- tion recently after the negative co-stimulator programmed cell death molecule-1 （ PD-1 ） and cytotoxic T cell associated antigen-4（ CTLA- 4） discovered. The expression spectrum of BTLA is situated between PD-1 and CTLA-4. It expresses not only in T cells,but also in B cells, NK cells,macrophages and dendritic cells. It mediates inhibitory signals to T cells when binding its ligand. It is suggested that BTLA signaling pathway might play a negative regulatory role in the anti-tumor immune response and associate with tumor immune es- cape mechanism. So it is likely to become a potential target of tumor biotherapy.